PARTNERSHIPS
Partner with us
We are committed to developing best-in-class therapeutics for immunological and inflammatory diseases and welcome the opportunity to explore collaborations with potential partners around the world.
Partners
Aditum and Miragene have partnered to establish Celexor Bio, a new biotechnology company. Celexor, partially owned by Miragene, has in-licensed global rights to MAG-018, an ILT7-targeting monoclonal antibody developed through our Smart Innovation platform.
Inmagene and HUTCHMED (China) Limited（"HUTCHMED"） (Nasdaq/AIM: HCM; HKEX: 13) have formed a strategic partnership to develop MAG-007 to treat a range of immunologic and inflammatory diseases. Led and funded by Inmagene, both products are in global clinical development.
MPM has in-licensed global rights to MAG-013, an IL-7Rα–targeting monoclonal antibody developed through our Smart Innovation platform, to support the launch of a new company.
To explore partnership opportunities, please contact our business development team by emailing bdpartner@miragene.com.